Fuji Pharma, JCR Pharmaceuticals Dissolve Partnership in Renal Anemia Drug Development.Tokyo, Japan, Nov 14, 2005 - (JCNN JCNN Japan Corporate News Network ) - Fuji Pharma has agreed with JCR JCR Journal Citation Reports JCR Java Content Repository (IBM) JCR Junior Common Room (British university term) JCR Journal of Clinical Rheumatology JCR Journal of Circadian Rhythms Pharmaceuticals to terminate their joint development contract for JR-013, a drug candidate for treating renal anemia anemia (ənē`mēə), condition in which the concentration of hemoglobin in the circulating blood is below normal. Such a condition is caused by a deficient number of erythrocytes (red blood cells), an abnormally low level of hemoglobin . Since November 2004, the two companies have collaborated in R&D for the candidate. However, the two companies have disagreed on the direction of development, future budget plans and related rights. Fuji Pharma will halt the development of JR-013. Meanwhile, JCR Pharmaceuticals will conduct clinical trials as originally planned with a view to forming a partnership with other companies. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion